The British pharma giant will hand off its experimental itch treatment to Italian company Alfasigma as it focuses on broader ...

In this installment in our series about diseases preventable by vaccination, we examine hepatitis A and why protection from ...

GSK and Alfasigma ink agreement on worldwide rights for linerixibat, an IBAT inhibitor for cholestatic pruritus in primary biliary cholangitis: London, UK Tuesday, March 10, 2026, ...

GSK’s linerixibat is currently under regulatory review in the US, Europe, and China, amongst other regions.

GSK has signed an eleventh-hour agreement to give Alfasigma rights to its primary biliary cholangitis (PBC) therapy ...

Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic ...

Alcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and liver-related mortality worldwide, with few effective therapies.

Detectable serum HBV RNA in chronic hepatitis B patients with undetectable viral DNA was associated with a 3.2-fold higher ...

Mirum Pharmaceuticals MIRM announced that it has completed enrollment in the phase III AZURE-1 study, evaluating its pipeline ...

LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver rarely shouts in the beginning. It whispers.Liver Function Tests, or LFTs, ...

Researchers at the University of São Paulo (USP) in Brazil have discovered a set of genes that can predict how viral hepatitis may progress in the body. They call this network of genes the ...

Protein aggregates as hallmarks of severe alcohol-related liver injuryAlcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and ...